促进和保护公众健康:欧盟药物警戒体系如何运作
本文概述了欧盟药物警戒体系,该体系通过实施修订后的药物警戒立法得以合理化和强化。文章介绍了体系目标、基本原则、组成部分及未来变革驱动因素。核心是药物警戒风险评估委员会负责评估药品风险管理的各个方面,确保欧盟市场药品最优使用,最大化获益并最小化风险。
要点
- 药物警戒风险评估委员会负责评估药品风险管理的所有方面。
- 体系目标是通过支持药品可及性和减少不良反应负担来促进和保护公众健康。
- 药物警戒已完全整合到药品生命周期中,从上市前开始规划。
核心结论
- 欧盟药物警戒体系通过主动、风险比例和以患者为中心的方法,促进和保护公众健康。
研究设计与样本
- 本文为对欧盟药物警戒体系的概述,源于修订后的药物警戒立法的实施。
主要发现
- 药物警戒风险评估委员会负责评估药品风险管理的所有方面,确保欧盟市场药品最优使用。
- 体系目标包括支持药品可及性(包括满足先前未满足医疗需求的药品)和减少药物不良反应负担。
- 药物警戒已完全整合到药品生命周期中,规划在药品上市前开始,并鼓励公司在开发早期为高创新产品开始规划。
- 授权后,药品安全性信息通过多种来源持续获取,包括药物不良反应的自发报告或监测真实世界数据。
临床怎么用
- 临床药师应了解药物警戒体系贯穿药品全生命周期,从上市前规划到上市后安全性监测。
- 在临床实践中,应关注药物不良反应的自发报告和真实世界数据监测,以支持药品风险最小化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article provides an overview of the European Union pharmacovigilance system resulting from the rationalisation and strengthening delivered through the implementation of the revised pharmacovigilance legislation. It outlines the system aims, underlying principles, components and drivers for future change. At its core, the Pharmacovigilance Risk Assessment Committee is responsible for assessing all aspects of the risk management of medicinal products, thus ensuring that medicines approved for the European Union market are optimally used by maximising their benefits and minimising risks. The main objectives of the system are to promote and protect public health by supporting the availability of medicines including those that fulfil previously unmet medical needs, and reducing the burden of adverse drug reactions. These are achieved through a proactive, risk proportionate and patient-centred approach, with high levels of transparency and engagement of civil society. In the European Union, pharmacovigilance is now fully integrated into the life cycle of medicinal products, with the planning of pharmacovigilance activities commencing before a medicine is placed on the market, and companies encouraged to start planning very early in development for high-innovation products. After authorisation, information on the safety of medicines continues to be obtained through a variety of sources, including spontaneous reports of adverse drug reactions or monitoring real-world data. Finally, the measurement of the impact of pharmacovigilance activities, auditing and inspections, as well as capacity building ensure that the system undergoes continuous improvement and can always rely on the best methodologies to safeguard public health.
引用
- Santoro A, Genov G, Spooner A, et al. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. Drug Saf. 2017. PMID: 28735357. doi:10.1007/s40264-017-0572-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。